Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Accumulating evidence suggests that a high tumour burden has a negative effect on
anticancer immunity. The concept of tumour burden, simply defined as the total amount of …

Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs)
in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we …

The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a
central focus for engaging the immune system in the fight against cancer. Basic science …

Even though the immuno-oncology (IO) era has achieved many successes, some signs of
research development deceleration are arising. Recently, the number of FDA …

The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …

Immune checkpoint blockade (ICB) can produce durable responses against cancer. We and
others have found that a subset of patients experiences paradoxical rapid cancer …

Background The early crossing of survival curves in randomised clinical trials (RCTs) with
immune checkpoint blockers suggests an excess of mortality in the first months of treatment …

Immunotherapy is often perceived as a relatively recent advance. In reality, however, one
should be looking for the beginnings of cancer immunotherapy under different names as far …

Ovarian cancer is the most lethal gynecologic malignancy. Surgery and chemotherapy are
the primary treatments for ovarian cancer; however, patients often succumb to recurrence …